Biofrontera Stock Forum

$Biofrontera (BFRI.US)$
Record-Breaking Year: Biofrontera Hits $37.3M Revenue as Cost Cuts Boost Bottom Line

$Biofrontera (BFRI.US)$ Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(3.22) per share which missed the analyst consensus estimate of $(0.85) by 278.82 percent. This is a 75.27 percent increase over losses of $(13.02) per share from the same period last year. The company reported quarterly sales of $37.32 million which missed the analyst consensus estimate of $47.06 million by 20.69 percent. This is a 9.54 percent increase over sales of $34.07 million the same period last year.

$Biofrontera (BFRI.US)$
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update
Friday, 21st March at 8:00 am
Conference scheduled for Friday, March 21, 2025 at 10:00 a.m. Eastern time
Woburn, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today reported financial results for the three and twelve months ended Dece...

$Biofrontera (BFRI.US)$
Major Milestone: Biofrontera's Skin Cancer Treatment Targets New Body Areas in Phase 3 Trial

$Biofrontera (BFRI.US)$
Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
Biofrontera Inc. (BFRI) has achieved a significant milestone in its Phase 3 study of Ameluz-PDT for treating superficial Basal Cell Carcinoma (sBCC), with the last patient completing the 1-year follow-up in December 2024. The study, involving 187 patients, demonstrated highly statistically significant...

$Biofrontera (BFRI.US)$ fly high $3+🚀🚀🚀🚀

$Biofrontera (BFRI.US)$ 😎

$Biofrontera (BFRI.US)$ Finally it's on

$Biofrontera (BFRI.US)$
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market
Monday, 23rd December at 9:30 am
Biofrontera started commercial distribution of the RhodoLED XL in June 2024 and has seen rapid uptake in the US market since launch.
The RhodoLED XL is approved by the FDA in combination with Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate severity on the face and scalp.
Biofr...